$NKTR
NEKTAR THERAPEUTICS Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024026249 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$21.64M	$23.89M	$90.12M
YoY Change	0.21%	8.45%	-2.1%
Cost Of Revenue	$8.534M	$7.283M	$33.77M
YoY Change	20.88%	16.85%	56.08%
Gross Profit	$13.11M	$16.60M	$56.35M
YoY Change	-9.83%	5.14%	-19.97%
Gross Profit Margin	60.56%	69.51%	62.53%
Selling, General & Admin	$20.15M	$17.32M	$77.42M
YoY Change	-4.42%	-21.05%	-16.15%
% of Gross Profit	153.75%	104.32%	137.38%
Research & Development	$27.41M	$29.94M	$114.2M
YoY Change	-10.05%	-13.81%	-47.71%
% of Gross Profit	209.14%	180.35%	202.58%
Depreciation & Amortization	$1.607M	$1.615M	$7.000M
YoY Change	-30.19%	-49.25%	-42.62%
% of Gross Profit	12.26%	9.73%	12.42%
Operating Expenses	$27.41M	$45.96M	$114.2M
YoY Change	-10.05%	-18.91%	-47.71%
Operating Profit	-$35.43M	-$29.36M	-$263.7M
YoY Change	-73.7%	-28.2%	-29.9%
Interest Expense	-$1.311M	-$2.350M	-$6.325M
YoY Change	-44.71%	-42.33%
% of Operating Profit
Other Income/Expense, Net	-$1.410M	-$6.247M	-$12.57M
YoY Change	-40.53%		-212.42%
Pretax Income	-$36.84M	-$42.11M	-$276.3M
YoY Change	-73.13%	-25.53%	-24.31%
Income Tax	-$35.00K	-$29.00K	-$200.0K
% Of Pretax Income
Net Earnings	-$36.80M	-$42.08M	-$276.1M
YoY Change	-73.14%	-29.5%	-25.03%
Net Earnings / Revenue	-170.07%	-176.17%	-306.31%
Basic Earnings Per Share	-$0.19		-$1.45
Diluted Earnings Per Share	-$0.19	-$0.22	-$1.45
COMMON SHARES
Basic Shares Outstanding	183.6M	190.8M	190.0M
Diluted Shares Outstanding	194.7M		190.0M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$289.2M	$303.6M	$303.6M
YoY Change	-36.69%	-39.88%	-39.88%
Cash & Equivalents	$48.64M	$35.28M	$35.28M
Short-Term Investments	$240.6M	$268.3M	$268.3M
Other Short-Term Assets	$10.74M	$9.779M	$9.779M
YoY Change	-2.42%	-38.14%	-38.14%
Inventory	$16.24M	$16.10M	$16.10M
Prepaid Expenses
Receivables	$3.617M	$1.205M	$1.205M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$319.8M	$330.7M	$330.7M
YoY Change	-34.87%	-39.43%	-39.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.48M	$18.86M	$36.86M
YoY Change	-35.48%	-41.89%	-57.08%
Goodwill		$0.00
YoY Change		-100.0%
Intangibles
YoY Change
Long-Term Investments	$36.78M	$25.83M	$25.83M
YoY Change
Other Assets	$4.656M	$4.644M	$4.644M
YoY Change	231.15%	106.86%	106.86%
Total Long-Term Assets	$76.18M	$67.33M	$67.33M
YoY Change	7.78%	-59.1%	-59.1%
TOTAL ASSETS
Total Short-Term Assets	$319.8M	$330.7M	$330.7M
Total Long-Term Assets	$76.18M	$67.33M	$67.33M
Total Assets	$396.0M	$398.0M	$398.0M
YoY Change	-29.5%	-43.99%	-43.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.757M	$9.848M	$9.848M
YoY Change	136.93%	-24.13%	-24.13%
Accrued Expenses	$24.28M	$22.16M	$41.42M
YoY Change	-35.09%	-59.87%	-24.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$52.41M	$51.27M	$51.27M
YoY Change	-12.48%	-24.83%	-24.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.334M	$4.635M	$215.8M
YoY Change	-33.11%	-38.62%	-21.75%
Total Long-Term Liabilities	$4.334M	$4.635M	$215.8M
YoY Change	-33.11%	-38.62%	-21.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.41M	$51.27M	$51.27M
Total Long-Term Liabilities	$4.334M	$4.635M	$215.8M
Total Liabilities	$269.3M	$267.0M	$267.0M
YoY Change	-16.07%	-22.36%	-22.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.514B	-$3.477B
YoY Change	5.27%	8.62%
Common Stock	$3.644B	$3.608B
YoY Change	1.66%	0.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.000M	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$126.7M	$131.0M	$131.0M
YoY Change
Total Liabilities & Shareholders Equity	$396.0M	$398.0M	$398.0M
YoY Change	-29.5%	-43.99%	-43.99%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$36.80M	-$42.08M	-$276.1M
YoY Change	-73.14%	-29.5%	-25.03%
Depreciation, Depletion And Amortization	$1.607M	$1.615M	$7.000M
YoY Change	-30.19%	-49.25%	-42.62%
Cash From Operating Activities	-$47.89M	-$47.01M	-$192.6M
YoY Change	-7.76%	-18.54%	-36.64%
INVESTING ACTIVITIES
Capital Expenditures	$157.0K	$265.0K	$865.0K
YoY Change	-63.74%	-48.24%	-84.76%
Acquisitions
YoY Change
Other Investing Activities	$19.42M	$17.63M	$140.4M
YoY Change	-52.68%	-56.5%	-62.2%
Cash From Investing Activities	$19.26M	$17.36M	$139.6M
YoY Change	-52.56%	-56.61%	-61.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	42.00M	30.00K	30.00K
YoY Change		-70.87%	-98.01%
NET CHANGE
Cash From Operating Activities	-47.89M	-47.01M	-192.6M
Cash From Investing Activities	19.26M	17.36M	139.6M
Cash From Financing Activities	42.00M	30.00K	30.00K
Net Change In Cash	13.37M	-29.61M	-52.95M
YoY Change	-218.57%	68.38%	-184.04%
FREE CASH FLOW
Cash From Operating Activities	-$47.89M	-$47.01M	-$192.6M
Capital Expenditures	$157.0K	$265.0K	$865.0K
Free Cash Flow	-$48.05M	-$47.27M	-$193.5M
YoY Change	-8.22%	-18.8%	-37.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	0-24006
CY2023	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2023	dei	City Area Code CityAreaCode	415
CY2023	dei	Local Phone Number LocalPhoneNumber	482-5300
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023	dei	Trading Symbol TradingSymbol	NKTR
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	109000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	183617817
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35277000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88227000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	268339000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	416750000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1205000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5981000
CY2023Q4	us-gaap	Inventory Net InventoryNet	16101000
CY2022Q4	us-gaap	Inventory Net InventoryNet	19202000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9779000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15808000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	330701000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	545968000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	25825000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18856000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32451000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18007000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	53435000
CY2023Q4	us-gaap	Goodwill Goodwill	0
CY2022Q4	us-gaap	Goodwill Goodwill	76501000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4644000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2245000
CY2023Q4	us-gaap	Assets Assets	398033000
CY2022Q4	us-gaap	Assets Assets	710600000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9848000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12980000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22162000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36557000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19259000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18667000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51269000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	68204000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	98517000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112829000
CY2023Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	112625000
CY2022Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	155378000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4635000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7551000
CY2023Q4	us-gaap	Liabilities Liabilities	267046000
CY2022Q4	us-gaap	Liabilities Liabilities	343962000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0
CY2022Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	191384000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	191384000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	188560000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	188560000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	19000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	19000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3608137000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3574719000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	80000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6907000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3477249000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3201193000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	130987000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	366638000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	398033000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	710600000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90122000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92055000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101907000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33768000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21635000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24897000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	114162000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	218323000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	400269000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	77417000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92333000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	122844000
CY2023	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	51958000
CY2022	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	135930000
CY2021	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	76501000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	353806000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	468221000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	548010000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-263684000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-376166000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-446103000
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-8023000
CY2023	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	25334000
CY2022	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	28911000
CY2021	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	47313000
CY2023	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0
CY2022	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0
CY2021	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	-24410000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	19009000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	6783000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	2731000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6247000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-116000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-162000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12572000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11183000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77177000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-276256000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-364983000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-523280000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3215000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-276056000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-368198000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523837000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.45
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.86
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.86
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	190001000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	190001000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	187138000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	187138000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	183298000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	183298000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-276056000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-368198000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523837000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1826000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1114000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1568000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5161000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1636000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-294000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6987000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2750000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1862000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-269069000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-370948000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-525699000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	33238000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94674000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-525699000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	758000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	57320000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-370948000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	366638000
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	30000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33388000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-269069000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	130987000
CY2023	us-gaap	Profit Loss ProfitLoss	-276056000
CY2022	us-gaap	Profit Loss ProfitLoss	-368198000
CY2021	us-gaap	Profit Loss ProfitLoss	-523837000
CY2023	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	68921000
CY2022	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	69794000
CY2021	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	77746000
CY2023	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	25334000
CY2022	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	28911000
CY2021	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	47313000
CY2023	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0
CY2022	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0
CY2021	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	-24410000
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-8023000
CY2023	nktr	Non Cash Research And Development Expense NonCashResearchAndDevelopmentExpense	0
CY2022	nktr	Non Cash Research And Development Expense NonCashResearchAndDevelopmentExpense	4951000
CY2021	nktr	Non Cash Research And Development Expense NonCashResearchAndDevelopmentExpense	16703000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33388000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57320000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94674000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7815000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13030000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14146000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-140000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2708000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-102000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	35328000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	65761000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	76501000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1300000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3326000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	nktr	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	2402000
CY2022	nktr	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	0
CY2021	nktr	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	0
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5099000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0
CY2023	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	14856000
CY2022	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	2435000
CY2021	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	-6730000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4776000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16511000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12397000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-699000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3401000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	509000
CY2023	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	8850000
CY2022	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	2680000
CY2021	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2340000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3583000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6906000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2586000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2884000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3103000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11690000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17124000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-19947000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-22926000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-192606000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-304007000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-412660000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	511699000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	467914000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	960689000
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	650883000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	826229000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1166951000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11504000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	865000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5676000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14989000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1245000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	13196000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	139564000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	365835000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	202777000
CY2023	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0
CY2022	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	750000
CY2021	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	3000000
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	30000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	758000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	33238000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1508000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36238000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-327000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-92000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-52950000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63009000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-173737000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88227000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25218000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35277000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88227000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25218000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1057000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2656000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	272000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	325000
CY2023Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	329400000
CY2023Q4	nktr	Investmnets Target Maturity Period InvestmnetsTargetMaturityPeriod	P2Y
CY2023	nktr	Investments Weighted Average Maturity Period InvestmentsWeightedAverageMaturityPeriod	P1Y
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11500000
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	500000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	700000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	294073000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	132000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35277000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88227000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	268339000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	416750000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	25825000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0
CY2023Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	329441000
CY2022Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	504977000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	82000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	294123000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	427726000
CY2023Q4	us-gaap	Cash Cash	17843000
CY2022Q4	us-gaap	Cash Cash	8798000
CY2023Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	329441000
CY2022Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	504977000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1800000
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7500000
CY2022Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7500000
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1861000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2575000
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12880000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10749000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1360000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5878000
CY2023Q4	us-gaap	Inventory Net InventoryNet	16101000
CY2022Q4	us-gaap	Inventory Net InventoryNet	19202000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9779000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15808000
CY2023Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	105015000
CY2022Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	154652000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	86898000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	124731000
CY2023Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	18117000
CY2022Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	29921000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	739000
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2530000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18856000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32451000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7000000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12200000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000000
CY2022Q4	us-gaap	Goodwill Goodwill	76501000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	76501000
CY2023Q4	us-gaap	Goodwill Goodwill	0
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	76500000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5553000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9582000
CY2023Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	4321000
CY2022Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	12262000
CY2023Q4	nktr	Liability To Collaboration Partners Current LiabilityToCollaborationPartnersCurrent	2678000
CY2022Q4	nktr	Liability To Collaboration Partners Current LiabilityToCollaborationPartnersCurrent	3808000
CY2023Q4	nktr	Accrued Contract Termination Costs Current AccruedContractTerminationCostsCurrent	3020000
CY2022Q4	nktr	Accrued Contract Termination Costs Current AccruedContractTerminationCostsCurrent	3902000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6590000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7003000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22162000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36557000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	12116000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	17057000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	19153000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	7027000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	10700000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	8974000
CY2023	us-gaap	Lease Cost LeaseCost	19143000
CY2022	us-gaap	Lease Cost LeaseCost	27757000
CY2021	us-gaap	Lease Cost LeaseCost	28127000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	21000000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	20100000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	16800000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19822000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	22255000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	22958000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	23682000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	24427000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	27303000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	140447000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22671000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	117776000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19259000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	98517000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2023	nktr	Subleases Income To Be Received SubleasesIncomeToBeReceived	10500000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1360000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1535000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	1589000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	1645000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	1702000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	1757000
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	9588000
CY2022Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	157461000
CY2012Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	0
CY2023	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	0
	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	274000000
CY2023	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	68921000
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	472166000
CY2023	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	25334000
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	298518000
CY2023	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	0
	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	10000000
CY2023	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	0
	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	-23522000
CY2023Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	113874000
CY2023Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	113874000
CY2023Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	1249000
CY2023Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	1249000
CY2023Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	112625000
CY2023Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	112625000
CY2023Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	3300000
CY2023Q4	us-gaap	Litigation Reserve LitigationReserve	0
CY2022Q4	us-gaap	Litigation Reserve LitigationReserve	0
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2926000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.07
CY2023	us-gaap	Business Exit Costs1 BusinessExitCosts1	5492000
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	7885000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	35328000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1300000
CY2023	us-gaap	Loss On Contract Termination LossOnContractTermination	1953000
CY2023	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	51958000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	67875000
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2114000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65761000
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	36962000
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1634000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	35328000
CY2023Q1	nktr	Impairment Of Remaining Long Lived Asset Held For Use ImpairmentOfRemainingLongLivedAssetHeldForUse	0
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	76500000
CY2023	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2023	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	38122000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23016000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M1D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33388000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57320000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94674000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	33100000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.04
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.012
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.884
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.779
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.638
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.18
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14088000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.4
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	11854000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.51
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6425000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.99
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M4D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17300000
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	12000000
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	12000000
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6000000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2500000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3600000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-274998000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-371900000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-524440000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1258000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	6917000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1160000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-276256000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-364983000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-523280000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-43000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-608000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	50000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-17000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1115000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	609000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-60000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	507000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	659000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-140000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2708000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-102000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-140000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2708000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-102000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3215000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-58013000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-76647000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-109889000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1192000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	987000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4727000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35033000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	51108000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	97914000
CY2023	nktr	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards	312000
CY2022	nktr	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards	12348000
CY2021	nktr	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards	286000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	8919000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	15778000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	6627000
CY2023	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	5320000
CY2022	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	6071000
CY2021	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	9936000
CY2023	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7838000
CY2022	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7112000
CY2021	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7891000
CY2023	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0
CY2022	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0
CY2021	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	4940000
CY2023	nktr	Income Tax Rate Reconciliation Impairment Of Goodwill IncomeTaxRateReconciliationImpairmentOfGoodwill	16065000
CY2022	nktr	Income Tax Rate Reconciliation Impairment Of Goodwill IncomeTaxRateReconciliationImpairmentOfGoodwill	0
CY2021	nktr	Income Tax Rate Reconciliation Impairment Of Goodwill IncomeTaxRateReconciliationImpairmentOfGoodwill	0
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1194000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2656000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3361000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3215000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	574737000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	545508000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	144128000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	142198000
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	39655000
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	38445000
CY2023Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	25384000
CY2022Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	28254000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	19447000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22110000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	34675000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	24134000
CY2023Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	6729000
CY2022Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	13424000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13863000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13935000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	858618000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	828008000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	854528000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	816235000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4090000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11773000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3824000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	11335000
CY2023Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	521000
CY2022Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	2451000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	265000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	392000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4610000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14178000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	520000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2405000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	38300000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30500000
CY2023Q4	nktr	Operating Loss Carryforwards Subject To Expiration OperatingLossCarryforwardsSubjectToExpiration	1300000000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	85845000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	80604000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78665000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	848000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	378000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2371000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	40079000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	5272000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	58000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	490000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	274000
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	409000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	126498000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	85845000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	80604000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2023	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2023	nktr	Unrecognized Tax Benefits Period Increase Decrease Reasonable Period Of Change UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange	P12M
CY2023	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1
CY2023	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90122000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92055000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101907000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
nktr-20231231_htm.xml	Edgar Link	completed
0000950170-24-026249-index-headers.html	Edgar Link	pending
0000950170-24-026249-index.html	Edgar Link	pending
0000950170-24-026249.txt	Edgar Link	pending
0000950170-24-026249-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img21475920_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20231231.htm	Edgar Link	pending
nktr-20231231.xsd	Edgar Link	pending
nktr-ex21_1.htm	Edgar Link	pending
nktr-ex23_1.htm	Edgar Link	pending
nktr-ex31_1.htm	Edgar Link	pending
nktr-ex31_2.htm	Edgar Link	pending
nktr-ex32_1.htm	Edgar Link	pending
nktr-ex97.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
NEKTAR THERAPEUTICS Stock $nktr

2024 Q1 Form 10-K Financial Statement

#000095017024026249 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR NEKTAR THERAPEUTICS Stock $nktr

2024 Q1 Form 10-K Financial Statement

#000095017024026249 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
NEKTAR THERAPEUTICS Stock $nktr